Thursday, October 29, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Peptide Ads: Why Google and Facebook Keep Saying No, and What Gets Approved?

Peptide ads are some of the hardest campaigns to get live on any major platform. I’ve watched founders with good products, clean lab reports, and real funding lose three ad…

TR
By Tom Reyes · Markets Editor
Oct 23 21:55 ETSource: TechBullion

From the source

Peptide Ads: Why Google and Facebook Keep Saying No, and What Gets Approved?

Peptide ads are some of the hardest campaigns to get live on any major platform. I’ve watched founders with good products, clean lab reports, and real funding lose three ad accounts in a month, then decide paid media “just doesn’t work” for their category. It does work. It runs on different rules than selling sneakers or software seats, that’s all.

Read at techbullion.com
PeptiPrescribed peptides from $99/moSee all →